Vaccinex (VCNX) has issued an update.
Vaccinex, Inc. has announced the completion of the final patient visit in its SIGNAL-AD Phase 1b/2 study, evaluating pepinemab as a treatment for Alzheimer’s disease. This milestone marks a significant step forward in the development of the drug, capturing the interest of investors and stakeholders in the potential impact on Alzheimer’s treatment and Vaccinex’s future prospects.
For a thorough assessment of VCNX stock, go to TipRanks’ Stock Analysis page.
